Pontin Acts as a Potential Biomarker for Poor Clinical Outcome and Promotes Tumor Invasion in Hilar Cholangiocarcinoma

Table 1

Relationships between the expression of Pontin and clinicopathological features in human hilar cholangiocarcinoma.

Clinicopathological features		Pontin
		Low	High
Gender				0.451
Male	54	31	23
Female	32	21	11
Age (years)				0.329
<60	41	27	14
≥60	45	25	20
Differentiation				0.062
Well/moderately	51	35	16
Poorly	35	17	18
Bismuth–Corlette classification				0.624
Type I	22	13	9
Type II	11	9	2
Type IIIa	12	7	5
Type IIIb	15	9	6
Type IV	26	14	12
Tumor size (cm)				0.299
<3	31	16	15
3–5	19	14	5
≥5	36	22	14
Tumor stage				0.127
T1	20	9	11
T2	27	20	7
T3	39	23	16
Lymph node metastasis				0.011
No	59	41	18
Yes	27	11	16
TNM stage				0.005
I	23	19	4
II	20	15	5
IIIa	16	7	9
IIIb	27	11	16

; .